Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

(2022) Henning Gruell et al.   NATURE MEDICINE

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

(2022) Samuel M. S. Cheng et al.   NATURE MEDICINE

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

(2021) Maria G. Noval et al.   Scientific Reports

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site

(2021) Taishi Onodera et al.   IMMUNITY

Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants

(2021) Angela Choi et al.   JOURNAL OF VIROLOGY

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

(2021) Emma C Wall et al.   LANCET

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

(2021) Rita E. Chen et al.   NATURE

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

(2021) Michael Dougan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

(2021) Takuya Tada et al.   mBio

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021

(2021) Heather M. Scobie et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies

(2021) Saathvik R. Kannan et al.   JOURNAL OF AUTOIMMUNITY

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

(2021) Chris Davis et al.   PLoS Pathogens

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

(2020) Alina Baum et al.   SCIENCE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2

(2020) Takuya Tada et al.   Cell Reports